Stonehaven Incubate has appointed Dr Gwynneth Thomas as Investment Manager based in London. Dr Thomas has extensive scientific and commercial experience in the areas of pathology, genomics, digital health, medical device and diagnostics.
Dr Mark Heffernan, CEO of Stonehaven Incubate, said: “Gwynneth has spent her career at the intersection of business and science, gaining significant experience in product growth, operations and fundraising, within, and on behalf of, early-stage human health companies. This includes over two years at the Texas Medical Center’s Innovation Institue in Houston, the largest medical center in the world, where she engaged over 50 human health start-up companies with the greater medical community, supporting them as they worked through various strategic business decisions.
“She is ideally suited to the role of Investment Manager here at Stonehaven Incubate where she will be able to help our clients with the creation and growth of new animal health companies.”
Dr Thomas’ roles within startup companies have been diverse and spanned across R&D, operations, quality management, business development, corporate strategy and fundraising – collectively raising over $10M. She holds a PhD in Molecular Pathology and a Masters of Business Administration from Wake Forest University in Winston Salem, NC.
ends
Notes to editor:
Stonehaven Incubate
Swiss based Stonehaven Incubate was formed in February 2018 and is a dedicated, animal health group committed to creating new companies de novo from disruptive human technology. Stonehaven Incubate works with innovators and builds strategies for new, stand-alone animal health companies. It finds experienced management teams and sources the required capital, leaving no stone unturned in its quest to bring human innovations to animal health.
Its parent company, Stonehaven Holding was formed in 2017 by George Gunn and Matthias Hofer. www.stonehaven-incubate.com
For more information contact Mike Keeler or Alistair Moses at Garnett Keeler PR on +44 (0)20 8647 4467 or mike.keeler@garnettkeeler.com / alistair.moses@garnettkeeler.com
STO/042/19
